Developer docs
API playgroundTry for free, no card

Search company profiles

Biomay AG

Full company profile

uuid003jxpd

Namestring
Biomay AG
Legal namestring
Biomay AG
Websiteurl
biomay.com
Company typeenum
Private
Founded yearint
1984
Descriptiontext

Biomay AG is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Vienna, Austria, operating as a one-stop manufacturer of three core biomolecules: plasmid DNA (pDNA), messenger RNA (mRNA), and recombinant proteins. Founded in 1984 and operating GMP manufacturing services since 2009, the company transitioned to a pure-play CDMO in 2019 and runs two integrated GMP facilities in Vienna totaling approximately 6,000 sqm — a 4,000 sqm headquarters in Aspern Seestadt focused on pDNA and recombinant proteins, and a 2,000 sqm mRNA Competence Center in the city's 9th district covering IVT, LNP formulation, QC labs, MSAT, and aseptic filling. Its proprietary platforms include in-house IVT and LNP formulation technology, scalable bioreactor capacity from 30L to 750L (with batch outputs from 100 mg up to 500 g of protein, 100 g of pDNA, and 50 g of mRNA), and a PPQ-validated E. coli-based Cas9 manufacturing process.

The company generates revenue through two streams: project-based GMP contract manufacturing services (process development, cell banking, GMP manufacturing, QC, aseptic filling, personalized batches with 4-week turnaround) and unit-based off-the-shelf catalog product sales through a webshop covering CRISPR/Cas9 nuclease, Cas9 mRNA variants, AAV and lentiviral starting plasmids, and recombinant allergens. Pricing is quote-based and not publicly disclosed for GMP services, while catalog items range from approximately €120 to €6,000 depending on grade (RUO vs GMP) and aliquot size. Its commercial footprint is predominantly Europe and the United States, served via direct enterprise sales, RFP-based engagement, and conference presence at CPhI, BIO Europe, ESGCT, ASGCT, and mRNA Health Conference events. Named anchor customers include BioNTech SE (DNA template supply for the Pfizer-BioNTech COVID-19 mRNA vaccine), Vertex Pharmaceuticals and CRISPR Therapeutics (cGMP manufacture of recombinant Cas9 for CASGEVY, the first FDA/EMA/MHRA-approved CRISPR/Cas9 therapy).

Biomay employs approximately 90 staff across its two Vienna sites, led by CEO Hans Huber (former Boehringer Ingelheim RCV bioprocess leader) and a senior team with deep CDMO and large-pharma pedigree. The company is privately owned with no disclosed VC or PE backing and operates without parent-company affiliation. Strategic priorities visible over 2024-2026 include FDA-approved commercial supply of Cas9 into the US market, an integrated end-to-end mRNA platform (now including LNP formulation), a growing off-the-shelf catalog franchise, the Areterna raw-materials partnership, and membership in the Alliance for mRNA Medicines.

Short descriptiontext

Biomay AG is a privately held Vienna-based CDMO offering GMP contract manufacturing of plasmid DNA, mRNA, and recombinant proteins, plus off-the-shelf catalog products, to biotech and pharma clients in Europe and the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVienna, Austria
HQ citystring
Vienna
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
GMP contract manufacturing, plasmid DNA production, mRNA manufacturing services, recombinant protein CDMO, biologics manufacturing services
Industry3 codes
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Contract Manufacturing Services
TypeProfessional Services
Description

Full-service Contract Development and Manufacturing Organization offering GMP manufacturing of plasmid DNA, mRNA, and recombinant proteins. Revenue generated through project-based contracts with biotech and pharma companies for clinical-stage and commercial manufacturing. Services include process development, cell banking, GMP manufacturing, quality control, and aseptic filling

biomay.com
2Off-the-Shelf Catalog Products
TypeOne Time License
Description

Sale of standardized products including CRISPR/Cas9 nuclease, Cas9 mRNA, AAV starting plasmids, lentiviral plasmids, and recombinant allergens through the company webshop. Products available in both RUO (research use only) and GMP grades. Revenue from unit-based product sales

biomay.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
Pricing details7 tiers
1CRISPR/Cas9 Nuclease RUO
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Recombinant spCas9 RUO: €350 (0.1 mg), €350-€6,000 range (0.1-5 mg)

biomay.com
2CRISPR/Cas9 Nuclease GMP
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Recombinant spCas9 GMP: Available in 2.5 mg and 5 mg aliquots - price upon request

biomay.com
3Cas9 mRNA RUO
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Cas9 mRNA (Cap1, 145A) RUO: €180 (25 µg) to €1,700 (1000 µg); Cas9 mRNA variants from €180 per unit

biomay.com
4AAV Starting Plasmids
ModelUnit PricingBilling cadencePay-as-you-go
Notes

AAV plasmids range from €120-€980 depending on serotype and aliquot size (1-10 mg RUO); GMP grades available upon request

biomay.com
5Lentivirus Plasmids
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Lentivirus plasmids (e.g., pBM-LV-VSVG RUO): €200-€1,650 depending on aliquot size

biomay.com
6Recombinant Allergens
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Research-grade recombinant allergens range from €560 to €1,699 per aliquot depending on allergen type and size (200-1000 µg)

biomay.com
7GMP Manufacturing Services
ModelOtherBilling cadenceMulti-year contract
Notes

Custom GMP manufacturing services are project-based and quote-driven. Pricing depends on product type, batch scale, quality requirements, and project scope

biomay.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Biomay AG is a GMP-licensed contract development and manufacturing organization (CDMO) headquartered in Vienna that produces plasmid DNA (pDNA), mRNA, and recombinant proteins using proprietary microbial expression platforms. The company provides end-to-end services spanning cell banking, upstream and downstream process development, GMP manufacturing, LNP formulation, and aseptic fill-finish for biotech and pharmaceutical clients. It also distributes a small catalog of research-use reagents and recombinant allergens.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 200+ GMP-manufactured plasmid batches delivered
+4 more records
Product overview1 text field

Biomay AG is a privately held, Vienna-based Contract Development and Manufacturing Organization (CDMO) offering GMP manufacturing services since 2009. The company operates as a one-stop manufacturer producing three core biomolecules: plasmid DNA (pDNA), messenger RNA (mRNA), and recombinant proteins. These are supported by comprehensive service offerings including GMP manufacturing, aseptic filling, personalized (patient-specific) batch production, and lipid nanoparticle (LNP) formulation services. Biomay's product portfolio also includes catalog products such as AAV and lentiviral starting plasmids, CRISPR/Cas9 nuclease, Cas9 mRNA, and recombinant allergens for research use. The company operates two GMP manufacturing sites in Vienna (headquarters in Seestadt Aspern and mRNA Competence Center in downtown Vienna) and is FDA-inspected.

Product and service12 records
1Plasmid DNA (pDNA) GMP Manufacturing
CategoryCDMO Services
Description

Contract GMP manufacturing of plasmid DNA for gene therapy, cell therapy, and DNA vaccine developers using proprietary microbial fermentation processes.

2mRNA GMP Manufacturing
CategoryCDMO Services
Description

Contract GMP manufacturing of mRNA active substance via in-vitro transcription, including personalized and batch mRNA production for therapeutic developers.

3Recombinant Protein Manufacturing
CategoryCDMO Services
Description

Contract GMP manufacturing of recombinant proteins expressed in microbial hosts (E. coli, yeast) including HQ-grade and GMP-grade batches.

4Aseptic Filling Services
CategoryCDMO Services
Description

Aseptic fill-finish of liquid vials for biologics, mRNA, and plasmid DNA products in a GMP environment.

5LNP Formulation Services
CategoryCDMO Services
Description

Lipid nanoparticle (LNP) formulation of mRNA and nucleic acid drug substances for vaccine and therapeutic clients.

6Personalized Batch Manufacturing
CategoryCDMO Services
Description

Small-scale, patient-specific GMP manufacturing of individualized mRNA or cell therapy drug substances for clinical use.

7HQ-Grade Recombinant Protein Production
CategoryCDMO Services
Description

High-quality (HQ) recombinant protein production service for pre-clinical and research-grade material using microbial expression.

8CRISPR/Cas9 Nuclease (catalog)
CategoryCatalogue Reagents
Description

Catalogue research-use recombinant Cas9 nuclease protein supplied to gene editing researchers.

9Cas9 mRNA (catalog)
CategoryCatalogue Reagents
Description

Catalogue in-vitro transcribed Cas9 mRNA for gene editing research applications.

10AAV Starting Plasmids (catalog)
CategoryCatalogue Reagents
Description

Catalogue adeno-associated virus (AAV) packaging and starting plasmids sold to gene therapy developers.

11Lentiviral Plasmids (catalog)
CategoryCatalogue Reagents
Description

Catalogue lentiviral vector plasmids sold to cell and gene therapy researchers.

12Recombinant Allergens (catalog)
CategoryCatalogue Reagents
Description

Catalogue recombinant allergen proteins produced in microbial hosts for allergy research, diagnostics, and therapeutic developers.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-10
Description

Biomay joined the Alliance for mRNA Medicines (AMM), the leading global organization dedicated to advancing mRNA and next-generation encoding RNA therapeutics and vaccines. Membership enables collaboration with industry leaders, contribution to setting industry standards, and support for development of safe and effective mRNA-based therapies worldwide. Biomay participates in AMM ASCENT annual meeting.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-18
Description

Strategic partnership between Areterna LLC and Biomay AG to jointly serve mRNA CDMO customers in Europe and North America. Areterna supplies low-cost GMP raw materials including cap analogs and animal-origin-free nucleoside triphosphates (NTPs). Biomay provides GMP manufacturing of mRNA, pDNA, and recombinant proteins. Partnership enables European and American customers access to Areterna's raw materials while leveraging Biomay's 40 years of experience and 15+ years of GMP manufacturing. Biomay utilizes Areterna's cap analogs in GMP mRNA batches with satisfactory performance, yield, and quality.

3BioNTech SE
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-17
Description

Partnership with BioNTech to support supply chain for manufacturing of Pfizer-BioNTech COVID-19 mRNA vaccine. Biomay supplies DNA template for in-vitro transcription of mRNA active ingredient. Agreement initiated during clinical development phase in Q1/2020. Biomay became formally qualified supplier for BioNTech, providing process development, GMP preparation of cell bank, manufacturing of circular DNA plasmid, and preparation of linear DNA template. Multiple batches of released DNA template produced and delivered in 2021.

biomay.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

World's largest CDMO offering microbial and mammalian-cell contract manufacturing for biologics, mRNA, and small molecules. Overlaps directly with Biomay on microbial pDNA, mRNA, and recombinant protein CDMO services, though at vastly larger scale and with a much broader modality portfolio.

TypeBroad incumbent
Description

Global CDMO offering microbial and mammalian GMP manufacturing for recombinant proteins, viral vectors, and nucleic acid-based therapeutics. Directly comparable to Biomay on microbial-based protein CDMO services for clinical and commercial supply.

TypeDirect peer
Description

Specialist nucleic acid CDMO historically focused on plasmid DNA, mRNA, and proteins for gene therapy and cell therapy developers. Highly comparable to Biomay in offering GMP pDNA and mRNA manufacturing with off-the-shelf catalog products (e.g., catalog Cas9); now part of Danaher, expanding scale.

TypeBroad incumbent
Description

Global CDMO network providing biologics manufacturing services including microbial and cell culture capabilities. Comparable to Biomay on contract GMP manufacturing for biological products, with broader service breadth.

TypeOthers
Description

Specialist in chromatographic purification for large DNA plasmids and viral vectors, now part of Sartorius. An existing technology partner of Biomay (May 2018 collaboration on double-digit gram-scale plasmid purification) and an adjacent enabling-technology peer in the plasmid/viral vector CDMO ecosystem.

TypeDirect peer
Description

Belgian-Japanese CDMO specializing in GMP plasmid DNA and oligonucleotide manufacturing for gene therapy and nucleic-acid applications. Closely comparable to Biomay's pDNA manufacturing platform with similar customer profile.

TypeDirect peer
Description

Specialist CDMO for mRNA, plasmid DNA, and nucleic acid reagents with both custom GMP services and a strong catalog product offering. Directly comparable to Biomay on mRNA and pDNA CDMO services, and an employer of Biomay's VP BD May Guo prior to Biomay.

TypeBroad incumbent
Description

Diversified life sciences and CDMO business (including viral vector CDMO Brammer Bio) serving pharma and biotech with GMP manufacturing. Overlaps with Biomay on nucleic acid and gene therapy manufacturing services, with materially larger scale.

TypeDirect peer
Description

Specialist GMP CDMO for biologics including recombinant proteins, viral vectors, and cell therapies, with a European (German/Swiss) footprint. Comparable to Biomay as a European-headquartered microbial-experienced CDMO serving clinical-stage developers.

10ReciBioPharm (Recipharm)
TypeDirect peer
Description

CDMO offering development and GMP manufacturing for biologics including microbial-derived proteins and nucleic-acid-based therapies. Directly comparable as a microbial-CDMO competitor; also a prior employer of Biomay's VP BD May Guo.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biomay AG

Biopharmaceutical CDMO Servicesbiomay.com

Biomay AG is a privately held Vienna-based CDMO offering GMP contract manufacturing of plasmid DNA, mRNA, and recombinant proteins, plus off-the-shelf catalog products, to biotech and pharma clients in Europe and the United States.

What Biomay AG does

Biomay AG is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Vienna, Austria, operating as a one-stop manufacturer of three core biomolecules: plasmid DNA (pDNA), messenger RNA (mRNA), and recombinant proteins. Founded in 1984 and operating GMP manufacturing services since 2009, the company transitioned to a pure-play CDMO in 2019 and runs two integrated GMP facilities in Vienna totaling approximately 6,000 sqm — a 4,000 sqm headquarters in Aspern Seestadt focused on pDNA and recombinant proteins, and a 2,000 sqm mRNA Competence Center in the city's 9th district covering IVT, LNP formulation, QC labs, MSAT, and aseptic filling. Its proprietary platforms include in-house IVT and LNP formulation technology, scalable bioreactor capacity from 30L to 750L (with batch outputs from 100 mg up to 500 g of protein, 100 g of pDNA, and 50 g of mRNA), and a PPQ-validated E. coli-based Cas9 manufacturing process.

The company generates revenue through two streams: project-based GMP contract manufacturing services (process development, cell banking, GMP manufacturing, QC, aseptic filling, personalized batches with 4-week turnaround) and unit-based off-the-shelf catalog product sales through a webshop covering CRISPR/Cas9 nuclease, Cas9 mRNA variants, AAV and lentiviral starting plasmids, and recombinant allergens. Pricing is quote-based and not publicly disclosed for GMP services, while catalog items range from approximately €120 to €6,000 depending on grade (RUO vs GMP) and aliquot size. Its commercial footprint is predominantly Europe and the United States, served via direct enterprise sales, RFP-based engagement, and conference presence at CPhI, BIO Europe, ESGCT, ASGCT, and mRNA Health Conference events. Named anchor customers include BioNTech SE (DNA template supply for the Pfizer-BioNTech COVID-19 mRNA vaccine), Vertex Pharmaceuticals and CRISPR Therapeutics (cGMP manufacture of recombinant Cas9 for CASGEVY, the first FDA/EMA/MHRA-approved CRISPR/Cas9 therapy).

Biomay employs approximately 90 staff across its two Vienna sites, led by CEO Hans Huber (former Boehringer Ingelheim RCV bioprocess leader) and a senior team with deep CDMO and large-pharma pedigree. The company is privately owned with no disclosed VC or PE backing and operates without parent-company affiliation. Strategic priorities visible over 2024-2026 include FDA-approved commercial supply of Cas9 into the US market, an integrated end-to-end mRNA platform (now including LNP formulation), a growing off-the-shelf catalog franchise, the Areterna raw-materials partnership, and membership in the Alliance for mRNA Medicines.

Biomay AG firmographics

Firmographics
Name
Biomay AG
Legal name
Biomay AG
Website
https://biomay.com
Company type
Private
Founded year
1984
Operating status
Operating
Headcount range
51–100 employees
Short description
Biomay AG is a privately held Vienna-based CDMO offering GMP contract manufacturing of plasmid DNA, mRNA, and recombinant proteins, plus off-the-shelf catalog products, to biotech and pharma clients in Europe and the United States.
Ownership category
akta.pro rank

Biomay AG industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • GMP contract manufacturing
  • Plasmid DNA production
  • MRNA manufacturing services
  • Recombinant protein CDMO
  • Biologics manufacturing services

Where Biomay AG is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
Austria
HQ region
Europe

Offices2 records

Markets served

Biomay AG business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

  1. CDMO Contract Manufacturing Services: Full-service Contract Development and Manufacturing Organization offering GMP manufacturing of plasmid DNA, mRNA, and recombinant proteins. Revenue generated through project-based contracts with biotech and pharma companies for clinical-stage and commercial manufacturing. Services include process development, cell banking, GMP manufacturing, quality control, and aseptic filling
  2. Off-the-Shelf Catalog Products: Sale of standardized products including CRISPR/Cas9 nuclease, Cas9 mRNA, AAV starting plasmids, lentiviral plasmids, and recombinant allergens through the company webshop. Products available in both RUO (research use only) and GMP grades. Revenue from unit-based product sales

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCRISPR/Cas9 Nuclease RUO
Unit PricingPay-as-you-goCRISPR/Cas9 Nuclease GMP
Unit PricingPay-as-you-goCas9 mRNA RUO
Unit PricingPay-as-you-goAAV Starting Plasmids
Unit PricingPay-as-you-goLentivirus Plasmids
Unit PricingPay-as-you-goRecombinant Allergens
OtherMulti-year contractGMP Manufacturing Services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Biomay AG product offering

Product offering

Core offering

Biomay AG is a GMP-licensed contract development and manufacturing organization (CDMO) headquartered in Vienna that produces plasmid DNA (pDNA), mRNA, and recombinant proteins using proprietary microbial expression platforms. The company provides end-to-end services spanning cell banking, upstream and downstream process development, GMP manufacturing, LNP formulation, and aseptic fill-finish for biotech and pharmaceutical clients. It also distributes a small catalog of research-use reagents and recombinant allergens.

Product overview

Biomay AG is a privately held, Vienna-based Contract Development and Manufacturing Organization (CDMO) offering GMP manufacturing services since 2009. The company operates as a one-stop manufacturer producing three core biomolecules: plasmid DNA (pDNA), messenger RNA (mRNA), and recombinant proteins. These are supported by comprehensive service offerings including GMP manufacturing, aseptic filling, personalized (patient-specific) batch production, and lipid nanoparticle (LNP) formulation services. Biomay's product portfolio also includes catalog products such as AAV and lentiviral starting plasmids, CRISPR/Cas9 nuclease, Cas9 mRNA, and recombinant allergens for research use. The company operates two GMP manufacturing sites in Vienna (headquarters in Seestadt Aspern and mRNA Competence Center in downtown Vienna) and is FDA-inspected.

Differentiator

Problem solved

Functional benefit

Products and services

  • Plasmid DNA (pDNA) GMP Manufacturing Contract GMP manufacturing of plasmid DNA for gene therapy, cell therapy, and DNA vaccine developers using proprietary microbial fermentation processes.
  • mRNA GMP Manufacturing Contract GMP manufacturing of mRNA active substance via in-vitro transcription, including personalized and batch mRNA production for therapeutic developers.
  • Recombinant Protein Manufacturing Contract GMP manufacturing of recombinant proteins expressed in microbial hosts (E. coli, yeast) including HQ-grade and GMP-grade batches.
  • Aseptic Filling Services Aseptic fill-finish of liquid vials for biologics, mRNA, and plasmid DNA products in a GMP environment.
  • LNP Formulation Services Lipid nanoparticle (LNP) formulation of mRNA and nucleic acid drug substances for vaccine and therapeutic clients.
  • Personalized Batch Manufacturing Small-scale, patient-specific GMP manufacturing of individualized mRNA or cell therapy drug substances for clinical use.
  • HQ-Grade Recombinant Protein Production High-quality (HQ) recombinant protein production service for pre-clinical and research-grade material using microbial expression.
  • CRISPR/Cas9 Nuclease (catalog) Catalogue research-use recombinant Cas9 nuclease protein supplied to gene editing researchers.
  • Cas9 mRNA (catalog) Catalogue in-vitro transcribed Cas9 mRNA for gene editing research applications.
  • AAV Starting Plasmids (catalog) Catalogue adeno-associated virus (AAV) packaging and starting plasmids sold to gene therapy developers.
  • Lentiviral Plasmids (catalog) Catalogue lentiviral vector plasmids sold to cell and gene therapy researchers.
  • Recombinant Allergens (catalog) Catalogue recombinant allergen proteins produced in microbial hosts for allergy research, diagnostics, and therapeutic developers.

Quantifiable outcome

  • 200+ GMP-manufactured plasmid batches delivered
  • +4 more outcomes

Companies that use Biomay AG

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Biomay AG technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Biomay AG partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Alliance for mRNA Medicines (AMM)minorStrategic or Co-development Partner · 10 September 2025Biomay joined the Alliance for mRNA Medicines (AMM), the leading global organization dedicated to advancing mRNA and next-generation encoding RNA therapeutics and vaccines. Membership enables collaboration with industry leaders, contribution to setting industry standards, and support for development of safe and effective mRNA-based therapies worldwide. Biomay participates in AMM ASCENT annual meeting.
  • Areterna LLCcoreStrategic or Co-development Partner · 18 September 2024Strategic partnership between Areterna LLC and Biomay AG to jointly serve mRNA CDMO customers in Europe and North America. Areterna supplies low-cost GMP raw materials including cap analogs and animal-origin-free nucleoside triphosphates (NTPs). Biomay provides GMP manufacturing of mRNA, pDNA, and recombinant proteins. Partnership enables European and American customers access to Areterna's raw materials while leveraging Biomay's 40 years of experience and 15+ years of GMP manufacturing. Biomay utilizes Areterna's cap analogs in GMP mRNA batches with satisfactory performance, yield, and quality.
  • BioNTech SEcoreStrategic or Co-development Partner · 17 May 2021Partnership with BioNTech to support supply chain for manufacturing of Pfizer-BioNTech COVID-19 mRNA vaccine. Biomay supplies DNA template for in-vitro transcription of mRNA active ingredient. Agreement initiated during clinical development phase in Q1/2020. Biomay became formally qualified supplier for BioNTech, providing process development, GMP preparation of cell bank, manufacturing of circular DNA plasmid, and preparation of linear DNA template. Multiple batches of released DNA template produced and delivered in 2021.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Biomay AG competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: World's largest CDMO offering microbial and mammalian-cell contract manufacturing for biologics, mRNA, and small molecules. Overlaps directly with Biomay on microbial pDNA, mRNA, and recombinant protein CDMO services, though at vastly larger scale and with a much broader modality portfolio.
  • AGC Biologics: Global CDMO offering microbial and mammalian GMP manufacturing for recombinant proteins, viral vectors, and nucleic acid-based therapeutics. Directly comparable to Biomay on microbial-based protein CDMO services for clinical and commercial supply.
  • Eurofins CDMO: Global CDMO network providing biologics manufacturing services including microbial and cell culture capabilities. Comparable to Biomay on contract GMP manufacturing for biological products, with broader service breadth.
  • Thermo Fisher Scientific (Patheon / Brammer Bio): Diversified life sciences and CDMO business (including viral vector CDMO Brammer Bio) serving pharma and biotech with GMP manufacturing. Overlaps with Biomay on nucleic acid and gene therapy manufacturing services, with materially larger scale.

Direct peers

  • Aldevron (Danaher): Specialist nucleic acid CDMO historically focused on plasmid DNA, mRNA, and proteins for gene therapy and cell therapy developers. Highly comparable to Biomay in offering GMP pDNA and mRNA manufacturing with off-the-shelf catalog products (e.g., catalog Cas9); now part of Danaher, expanding scale.
  • Kaneka Eurogentec: Belgian-Japanese CDMO specializing in GMP plasmid DNA and oligonucleotide manufacturing for gene therapy and nucleic-acid applications. Closely comparable to Biomay's pDNA manufacturing platform with similar customer profile.
  • TriLink BioTechnologies ( Maravai LifeSciences): Specialist CDMO for mRNA, plasmid DNA, and nucleic acid reagents with both custom GMP services and a strong catalog product offering. Directly comparable to Biomay on mRNA and pDNA CDMO services, and an employer of Biomay's VP BD May Guo prior to Biomay.
  • Celonic Group: Specialist GMP CDMO for biologics including recombinant proteins, viral vectors, and cell therapies, with a European (German/Swiss) footprint. Comparable to Biomay as a European-headquartered microbial-experienced CDMO serving clinical-stage developers.
  • ReciBioPharm (Recipharm): CDMO offering development and GMP manufacturing for biologics including microbial-derived proteins and nucleic-acid-based therapies. Directly comparable as a microbial-CDMO competitor; also a prior employer of Biomay's VP BD May Guo.

Others

  • BIA Separations (Sartorius): Specialist in chromatographic purification for large DNA plasmids and viral vectors, now part of Sartorius. An existing technology partner of Biomay (May 2018 collaboration on double-digit gram-scale plasmid purification) and an adjacent enabling-technology peer in the plasmid/viral vector CDMO ecosystem.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Biomay AG social profiles

Digital presence

Biomay AG compliance and trust

Trust signal

Compliance4 records

Biomay AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biomay AG leadership team

Management profile

Number of profiles

Profiles9 records

Biomay AG subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Biomay AG funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biomay AG M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biomay AG

What does Biomay AG do?

Biomay AG is a GMP-licensed contract development and manufacturing organization (CDMO) headquartered in Vienna that produces plasmid DNA (pDNA), mRNA, and recombinant proteins using proprietary microbial expression platforms. The company provides end-to-end services spanning cell banking, upstream and downstream process development, GMP manufacturing, LNP formulation, and aseptic fill-finish for biotech and pharmaceutical clients. It also distributes a small catalog of research-use reagents and recombinant allergens.

Is Biomay AG a public or private company?

Biomay AG is a private company. It is classified as unknown and is currently operating.

When was Biomay AG founded?

Biomay AG was founded in 1984. It employs 51 to 100 people.

Where is Biomay AG based?

Biomay AG is headquartered in Vienna, Austria, in the Europe region.

How does Biomay AG make money?

Two revenue lines are on record. CDMO Contract Manufacturing Services are the primary driver. The others are off-the-Shelf Catalog Products.

Who are Biomay AG's main competitors?

Broad incumbents on record are Lonza Group, AGC Biologics, Eurofins CDMO and Thermo Fisher Scientific (Patheon / Brammer Bio). Direct peers are Aldevron (Danaher), Kaneka Eurogentec, TriLink BioTechnologies ( Maravai LifeSciences), Celonic Group and ReciBioPharm (Recipharm). BIA Separations (Sartorius) is listed as an others.

Does Biomay AG have an API?

No public API is recorded for Biomay AG.

What industry is Biomay AG in?

Biomay AG's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireMessenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Research and Global Forecast Report 2026-2035The mRNA vaccine contract development and manufacturing organization (CDMO) market is projected to grow from $8.41 billion in 2025 to $17.1 billion by 2030, driven by demand for COVID-19 vaccines, expanding biotech startups, and limited in-house manufacturing capacity. Key trends include lipid nanoparticle formulation services, rapid mRNA process scale-up, and integrated fill-finish outsourcing, with strategic partnerships such as Areterna LLC's collaboration with Biomay AG in September 2024 strengthening the market landscape. GenScript Biotech Corporation launched a GMP-like mRNA manufacturing service in May 2025, while tariffs on bioprocess equipment continue to influence operational costs in North America and Europe.PharmiWeb.comPlasmid DNA Manufacturing Market Report 2025-2035, with Profiles of AGC Biologics, Aldevron, Biomay, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, VGXI, and More - ResearchAndThe global plasmid DNA manufacturing market is projected to grow from USD 0.1 billion in 2025 to USD 0.53 billion by 2035, a CAGR of 14.85%. Growth is driven by cell and gene therapy development, with over 70 service providers and more than 50% offering GMP-grade services.PR NewswireInsights on the Allergy Immunotherapies Global Market to 2027 - by Treatment Type, Allergy Type, Distribution Channel and RegionResearchAndMarkets published a global market report estimating the allergy immunotherapies market reached US$ 2.56 billion in 2021 and is projected to grow to US$ 4.63 billion by 2027, at a compound annual growth rate of 10.2% during 2022-2027. Market growth is driven by rising allergy prevalence globally, increasing healthcare expenditure, growing awareness of immunotherapy treatments, and advancements in drug development technologies and allergy diagnostics. The report analyzes the competitive landscape including ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Group, DBV Technologies, Merck Group, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG.PR NewswireAllergy Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025Reportlinker published a market research report on the global allergy immunotherapy market covering the forecast period from 2017 to 2025, analyzing market segments by treatment type (SCIT and SLIT), allergy type, distribution channel, and region. The report identifies major industry players including Stallergenes Greer, Aimmune Therapeutics, ALK-Abello A/S, Allergy Therapeutics, Merck KGaA (Allergopharma), HAL Allergy Group, DBV Technologies, Circassia, Biomay AG, and Anergis. The market has been geographically segmented across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.